… are reportedly eyeing an antibody-drug conjugate deal with Henlius. … cardiovascular biotech, offers Mabwell up to $1B for siRNA asset … Kalexo will develop the drug for dyslipidemia and high-risk … -patient trial showed the drug reduced seizure frequency by …

… 2MW7141, a novel dual-target siRNA candidate for lipid management in … , a novel dual-target siRNA candidate for lipid management in … unmet need. To speed these drugs to market, Aditum Bio … on the translational phase of drug development. This model enables a …

… the formation of a new biotech company, Kalexo Bio, focused … a novel dual-target siRNA candidate designed for lipid … therapeutic approach targeting multiple genetic pathways involved in lipid … incubator-style model for drug development, will provide full …

Mabwell Bioscience Co. Ltd. and Aditum Bio Management Co. LLC announced, in after-market hours Sept. 17, an agreement to forge a new company called Kalexo Bio Inc. and load the biotech with a preclinical dyslipidemia asset via a potential $1 billion global …

… a new small interfering RNA (siRNA) candidate, 2MW7141.  The … to advance this promising siRNA therapy into the clinic.”  … received the US Food and Drug Administration (FDA) fast … track designation for its antibody-drug conjugate (ADC), 9MW2821, targeting …

… partnership with California-based Summit Therapeutics, which in December 2022 … ” for antibody drug development with a global pharma company, she … to Xia, the Chinese biotech sector provides a “conducive … , such as mRNA and siRNA therapies, as well as …

Endocrine/metabolic Rona Therapeutics Co. Ltd. has announced an … obesity. RN-3161, a novel siRNA developed through Rona’s proprietary …

… wide variety of biological drugs.”  From problem to platform … key to protecting delicate drugs like RNA and proteins … to real-world vaccine or drug delivery challenges. Citation: “Thermoreversibly … and Delivery of Protein and siRNA Biologics,” Hossainy et al,  …

… is a late-stage clinical biotechnology company dedicated to transforming cutting … the treatment of complement-mediated, genetic, cardiovascular, thrombosis, central nervous … to develop small interfering RNA (siRNA) therapeutics across multiple disease areas, …